Objective: Overproduction of nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) plays an important role in the pathogenesis of osteoarthritis (OA). In the present study, we determined the effect of trichostatin A (TSA) and butyric acid (BA), two histone deacetylase (HDAC) inhibitors, on NO and PGE 2 synthesis, inducible NO synthase (iNOS) and cyclooxygenase (COX)-2 expression, and nuclear factor (NF)-kB DNA-binding activity, in interleukin-1b (IL-1)-stimulated human OA chondrocytes, and on IL-1-induced proteoglycan degradation in cartilage explants.
Introduction
Osteoarthritis (OA) is the most common joint disorder and a leading cause of disability among the elderly population. It is characterized by progressive degenerative structural changes in articular cartilage, leading to loss of joint function. It is also characterized by excessive production of several inflammatory mediators 1e3 . Among these mediators, the pro-inflammatory cytokine interleukin-1b (IL-1) plays a pivotal role in the pathophysiology of OA. It induces a cascade of inflammatory and catabolic events in chondrocytes including the synthesis of prostaglandin E 2 (PGE 2 ) and nitric oxide (NO). IL-1 also alters chondrocyte anabolism by suppressing the synthesis of proteoglycan and collagen and by enhancing the production of matrix metalloproteinases (MMPs) 1e3 . NO is synthesized from L-arginine by a family of NO synthases (NOSs) of which three isoforms have been identified. Neuronal NOS (nNOS) and endothelial NOS (eNOS) are constitutively expressed, while the inducible NOS (iNOS) is expressed following stimulation with a variety of inflammatory agents such as endotoxins or cytokines 4 . NO promotes inflammation by enhancing the production of inflammatory cytokines 5 and PGE 2 6 and by reducing the synthesis of endogenous IL-1 receptor antagonist (IL-1 Ra) 7 . NO is also considered a potent catabolic agent in OA since it inhibits collagen and proteoglycan synthesis 8, 9 , stimulates the production and activation of MMPs 10 and induces chondrocyte apoptosis 11 . Accordingly, the in vivo selective inhibition of iNOS in an experimental model of OA reduces the joint structural changes and the expression of several inflammatory and catabolic factors, including IL-1 and MMP-1 12 . The biosynthesis of PGE 2 from arachidonic acid (AA) involves multiple enzymes including, cyclooxygenases (COXs). Two isoforms of COX have been identified: COX-1 is constitutively expressed in most tissues, whereas COX-2 is induced by various stimuli such as endotoxins, growth factors and pro-inflammatory cytokines 13 . PGE 2 is the most abundant prostanoid in arthritic joint and one of the major catabolic mediators involved in cartilage resorption. PGE 2 elicits cartilage resorption by enhancing the activation and production of MMPs and the degradation of cartilage matrix components 14, 15 and by promoting chondrocyte apoptosis 16 . In addition PGE 2 mediates pain responses and potentiates the effects of other inflammatory mediators 13 . Acetylation and deacetylation of nucleosomal histones play an important role in the regulation of gene expression 17, 18 . The histone acetylation status is controlled by the opposing actions of two classes of enzymes: histone acetyl transferases (HATs) and histone deacetylases (HDACs). Acetylation of histones loosens nucleosomal structures, thereby promoting gene transcription. In contrast, deacetylation of histones stabilizes nucleosomal structures and represses gene transcription 17, 18 . However, emerging evidence indicates that gene regulation by acetylation/deacetylation is more dynamic and complex, and that HATs can act as repressors and HDAC as activators of transcription. Indeed, global analysis of gene expression has shown that inhibition of HDAC activity results both in induction and repression of gene expression 19e24 . In recent years, significant interest has emerged in the inhibition of HDAC activity as a possible anti-cancer treatment. HDAC inhibitors induce growth arrest, differentiation and apoptosis of cancer cells in vitro and reduce the growth of experimental tumors in vivo 25, 26 . Presently, several HDAC inhibitors are in clinical trials for the treatment of solid and hematological tumors 27, 28 . In addition to their anti-cancer effects, recent studies have demonstrated that HDAC inhibitors modulate inflammatory responses. For instance, HDAC inhibitors reduce the production of IL-1, tumor necrosis factor-a (TNF-a), and interferon-g (IFN-g) in lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells 29, 30 . Likewise, HDAC inhibitors prevent LPS-induced production of TNF-a, IL-6 and reactive oxygen species in neuroglia cultures, and primary microglia 31e33 . HDAC inhibitors have also been reported to suppress IL-12 production in dendritic cells and macrophages 34 . However, it is currently unknown whether HDAC inhibitors regulate inflammatory responses in articular chondrocytes.
Since excessive production of the inflammatory mediators NO and PGE 2 plays an important role in the pathogenesis of OA, we assessed the effect of two HDAC inhibitors, trichostatin A (TSA) and butyric acid (BA), on the production of NO and PGE 2 in primary cultured human chondrocytes stimulated with IL-1. We additionally analyzed the expression of iNOS and COX-2 as well as the binding activity of transcription factor nuclear factorkB (NF-kB).
Materials and methods

REAGENTS
Recombinant human (rh) IL-1b was obtained from Genzyme (Cambridge, MA, USA), rhTNF-a and rhIL-17 were from R&D Systems (Minneapolis, MN, USA). TSA and BA were from SigmaeAldrich Canada (Oakville, ON, Canada). Dulbecco's modified Eagle's medium (DMEM), penicillin and streptomycin, fetal calf serum (FCS), and TRIzol Ò reagent were from Invitrogen (Burlington, ON, Canada). All other chemicals were purchased from either Sigmae Aldrich Canada or Bio-Rad (Mississauga, ON, Canada).
SPECIMEN SELECTION AND CHONDROCYTE CULTURE
Human normal cartilage (from femoral condyles) was obtained at necropsy, within 12 h of death, from donors with no history of arthritic disease (n ¼ 7, mean AE SD age: 54 AE 16 years). To ensure that only normal tissue was used, cartilage specimens were thoroughly examined both macroscopically and microscopically. Only those with no alterations were further processed. Human OA cartilage samples from femoral condyles and tibial plateaus were obtained from OA patients undergoing total knee replacement (n ¼ 47, mean AE SD age: 66 AE 12 years). All OA patients were diagnosed according to the criteria developed by the American College of Rheumatology Diagnostic Subcommittee for OA 35 . At the time of surgery, the patients had symptomatic disease requiring medical treatment in the form of non-steroidal anti-inflammatory drugs (NSAIDs) or selective COX-2 inhibitors. Patients who had received intra-articular injections of steroids were excluded. The Clinical Research Ethics Committee of Notre-Dame Hospital approved the study protocol and the use of human articular tissues.
Chondrocytes were released from cartilage by sequential enzymatic digestion as previously described 36 . In brief, this consisted of 2 mg/ml pronase for 1 h followed by 1 mg/ml collagenase (type IV; SigmaeAldrich) for 6 h at 37 C in DMEM and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin). The digested tissue was briefly centrifuged and the pellet was washed. The isolated chondrocytes were seeded at high density in tissue culture flasks and cultured in DMEM supplemented with 10% heat-inactivated FCS. At confluence, the chondrocytes were detached, seeded at high density, and allowed to grow in DMEM, supplemented as above. The culture medium was changed every second day, and 24 h before the experiment the cells were incubated in fresh medium containing 0.5% FCS. Only first passaged chondrocytes were used.
NO AND PGE 2 DETERMINATIONS
The nitrite levels, used as an indicator of NO production, were determined using the Griess assay as previously described 36 . The levels of PGE 2 were determined using a PGE 2 enzyme immunoassay from Cayman Chemical (Ann Arbor, MI, USA). The detection limit and sensitivity was 9 pg/ml. All assays were performed in duplicate.
WESTERN BLOT ANALYSIS
Chondrocytes were lysed in ice-cold lysis buffer (50 mM TriseHCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethansulfonylfluorid (PMSF), 10 mg/ml each of aprotinin, leupeptin, and pepstatin, 1% NP-40, 1 mM Na 3 VO 4 , and 1 mM NaF). Lysates were sonicated on ice and centrifuged at 12,000 rpm for 15 min. The protein concentration of the supernatant was determined using the bicinchoninic acid method (Pierce, Rockford, IL, USA). Twenty microgram of total cell lysate was subjected to SDS-polyacrylamide gel electrophoresis and electrotransferred to a nitrocellulose membrane (Bio-Rad). After blocking in 20 mM TriseHCl pH 7.5 containing 150 mM NaCl, 0.1% Tween 20, and 5% (w/v) non-fat dry milk, blots were incubated overnight at 4 C with the primary antibody and washed with a Tris buffer [Tris-buffered saline (TBS) pH 7.5, with 0.1% Tween 20] . The blots were then incubated with horseradish peroxidase-conjugated secondary antibody (Pierce), washed again, incubated with SuperSignal Ultra Chemiluminescent reagent (Pierce), and exposed to Kodak X-Omat film (Eastman Kodak Ltd, Rochester, NY, USA).
RNA EXTRACTION AND REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA from stimulated chondrocytes was isolated using the TRIzol 
REAL-TIME PCR
Real-time PCR analysis was performed in a total volume of 50 ml containing template DNA, 200 nM of sense and antisense primers, 25 ml of SYBR Ò Green master mix (QIAGEN, Mississauga, ON, Canada) and uracil-N-glycosylase (UNG, 0.5 Unit, Epicentre Technologies, Madison, WI, USA). After incubation at 50 C for 2 min (UNG reaction), and at 95 C for 10 min (UNG inactivation and activation of the AmpliTaq Gold enzyme), the mixtures were subjected to 40 amplification cycles (15 s at 95 C for denaturation and 1 min for annealing and extension at 60 C). Incorporation of SYBR Ò Green dye into PCR products was monitored in real-time using a GeneAmp 5700 Sequence detection system (Applied Biosystems, Foster City, CA, USA) allowing determination of the threshold cycle (C T ) at which exponential amplification of PCR products begins. After PCR, dissociation curves were generated with one peak, indicating the specificity of the amplification. A threshold cycle (C T value) was obtained from each amplification curve using the software provided by the manufacturer (Applied Biosystems).
Relative mRNA expression in chondrocytes was determined using the DDC T method, as detailed in the manufacturer's guidelines (Applied Biosystems). A DC T value was first calculated by subtracting the C T value for the housekeeping gene GAPDH from the C T value for each sample. A DDC T value was then calculated by subtracting the DC T value of the control (unstimulated cells) from the DC T value of each treatment. Fold changes compared with the control were then determined by raising two to the ÀDDC T power. Each PCR reaction generated only the expected specific amplicon as shown by the melting-temperature profiles of the final product and by gel electrophoresis of test PCR reactions. Each PCR was performed in triplicate on two separate occasions for each independent experiment.
PROTEOGLYCAN RELEASE
Cartilage proteoglycan degradation was assessed by measuring sulfated glycosaminoglycan (GAG) released into culture media using dimethyl methylene blue (DMMB) with chondroitin sulfate as a standard 37 . Results are expressed as mg of GAG released/mg cartilage.
NUCLEAR EXTRACT PREPARATION AND ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)
Nuclear extracts were prepared as previously described 38 . Briefly, chondrocytes were washed in ice-cold phosphate buffered saline (PBS) and gently scraped in ice-cold hypotonic buffer containing 10 mM hydroxyethylpiperazine ethane sulfonic acid (HEPES)eKOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM dithiotheritol (DTT), 1 mM PMSF, 1 mM Na 3 VO 4 and 10 mg/ml of aprotinin, leupeptin, and pepstatin. The cells were allowed to swell on ice and the nuclei were recovered by brief centrifugation. The pellets were resuspended in high salt buffer containing 20 mM HEPES, pH 7.9, 420 mM NaCl, 1.2 mM MgCl 2 , 0.5 mM DTT, 0.2 mM ethylenediaminetetraacetic acid (EDTA), 25% glycerol, 0.5 mM PMSF, 1 mM Na 3 VO 4 and 10 mg/ml of aprotinin, leupeptin, and pepstatin, followed by incubation on ice for 20 min. The nuclear extracts were recovered by centrifugation and protein concentration was determined using the Bradford method (Bio-Rad). A synthetic double-stranded oligonucleotide containing the kB consensus sequence 5 0 -AGTTGAGGGGACTTTCCCAGGC-3 0 was end-labeled by T4 polynucleotide kinase in the presence of [g-
32
P] adenosine triphosphate (ATP). The mutant competitor oligonucleotide had the following sequence with a 1 bp substitution (underlined): 5 0 -AGTTGAGGC-GACTTTCCCAGGC-3 0 . The binding buffer consisted of 10 mM TriseHCl, pH 7.5, 50 mM NaCl, 0.5 mM DTT, 0.5 mM EDTA, 1 mM MgCl 2 , 4% glycerol and 2.5 mg poly (dIedC). Binding reactions were conducted with 5 mg nuclear extract and 100,000 cpm 32 [P]-labeled oligonucleotide probe at 22 C for 20 min in a final volume of 10 ml. In supershift assays, the antibody to p65 (1 mg/reaction) was incubated with the reaction mixture for 1 h at 4
C before the addition of 32 [P]-labeled oligonucleotide. In cold competition assays, 50-fold molar excess of cold wild-type or mutant oligonucleotide was used. Binding complexes were resolved on non-denaturating 6% polyacrylamide gel electrophoresis in Triseborate buffer system, after which the gels were fixed, dried, and subjected to autoradiography.
STATISTICAL ANALYSIS
Data are expressed as the mean AE S.E.M. Statistical significance was assessed by the two-tailed Student's t test. P values less than 0.05 were considered statistically significant.
Results
TSA AND BA ATTENUATE IL-1-INDUCED NO AND PGE 2 PRODUCTION IN HUMAN CHONDROCYTES
Chondrocytes were stimulated with 100 pg/ml IL-1 in the absence or presence of increasing concentrations of two HDAC inhibitors, TSA and BA, and the production of NO was evaluated using Griess reagent. As shown in Fig. 1(A) , treatment with either TSA or BA suppressed IL-1-induced NO production in a dose-dependent manner. Similarly, the production of PGE 2 was dose-dependently suppressed in the presence of each HDAC inhibitor [ Fig. 1(B) ]. In another set of experiments, we found that TSA and BA also dosedependently inhibited IL-1-induced NO and PGE 2 production in normal chondrocytes, (n = 3, data not shown). The observed inhibition was not a result of reduced cell viability as confirmed by the methyl thiazolyl tetrazolium (MTT) assay (data not shown). The pro-inflammatory cytokines TNF-a and IL-17 also contribute to the pathogenesis of OA and are potent inducers of NO and PGE 2 production 1e3 . Therefore, we examined whether HDAC inhibition could also attenuate TNF-a and IL-17-induced NO and PGE 2 production. As shown in Fig. 2 , stimulation of chondrocytes with TNF-a or IL-17 dramatically increased the production of NO and PGE 2 . Interestingly, the induction of NO and PGE 2 production by TNF-a or IL-17 was almost completely abolished after treatment with TSA or BA. These data suggest that the suppressive effect of HDAC inhibitors was not specific to IL-1, and that HDAC inhibitors might target common pathways implicated in NO and PGE 2 production.
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TSA AND BA DECREASE IL-1-INDUCED iNOS AND COX-2 EXPRESSION IN CHONDROCYTES
To determine whether the inhibition of IL-1-induced NO and PGE 2 production is due to reduced iNOS, and COX-2 protein expression, the effects of HDAC inhibitors on the expression of both proteins were analyzed by Western blotting. Under basal conditions, iNOS and COX-2 proteins were undetectable and treatment with IL-1 resulted in a strong induction of both protein expressions (Fig. 3) . Consistent with their effects on NO and PGE 2 production, HDAC inhibitors prevented the induction of iNOS and COX-2 protein expression by IL-1, in a concentration-dependent manner (Fig. 3) . The levels of b-actin and COX-1 were not influenced by IL-1 alone or in combination with each HDAC inhibitors (Fig. 3) . IL-1-induced iNOS and COX-2 protein expression was also inhibited by TSA and BA in normal chondrocytes (n ¼ 3, data not shown). As expected, the induction of iNOS and COX-2 proteins by TNFa or IL-17 was also suppressed by each HDAC inhibitor (Fig. 4) .
Next, we used real-time PCR to determine whether HDAC inhibitors modulate iNOS and COX-2 mRNAs' induction. The relative expression level of each gene mRNA was plotted as fold changes over untreated control cells. GAPDH gene expression was used for normalization. As expected, IL-1 induced a marked increase of both iNOS and COX-2 mRNA levels (Fig. 5) . Treatment with either TSA or BA dose-dependently suppressed the induction of iNOS and COX-2 mRNA expression (Fig. 5) , suggesting that HDAC inhibitors exert their effects at the transcriptional To investigate the effect of HDAC inhibitors on IL-1-induced proteoglycan degradation, cartilage explants were incubated in DMEM with 10% FBS for 48 h and then transferred to medium containing 0.5% FBS and re-incubated for an additional 48 h. Thereafter, the explants were stimulated with IL-1 in the absence or presence of increasing concentrations of TSA or BA for 72 h, and GAG release into the supernatants was determined 37 . As shown in Fig. 6 , IL-1-induced GAG release was inhibited in a dose-dependent manner by either TSA or BA.
TSA AND BA DO NOT IMPAIR NF-kB-BINDING TO THE iNOS AND COX-2 PROMOTERS
The transcription factor NF-kB, mainly composed of p50 and p65 dimers, plays a pivotal role in mediating the effects of IL-1 in chondrocytes 39, 40 . Therefore, we performed EMSA to determine whether HDAC inhibitors modulate IL-1 effects by interfering with the DNA-binding activity of NF-kB. Nuclear extracts from chondrocytes treated with IL-1 alone, or in combination with increasing concentrations of HDAC inhibitors for 1 h, were used for these assays. As shown in Fig. 7 , IL-1 treatment induced a prominent increase in the DNA-binding activity of NF-kB. Interestingly, treatment with each HDAC inhibitor did not decrease the DNA-binding activity of NF-kB at any concentration point. The specificity of DNA-binding was confirmed using unlabeled wild-type and mutant oligonucleotides. The specificity was further evidenced using supershift assays and a specific anti-p65 antibody. Together these data suggest that HDAC inhibitors modulate IL-1 effects in chondrocytes without interfering with the DNA-binding activity of NF-kB.
Discussion
In the present study we demonstrated that inhibition of HDACs by two structurally unrelated HDAC inhibitors, TSA and BA, results in a dose-dependent suppression of IL-1-induced NO and PGE 2 production. The inhibition of NO and PGE 2 production was concomitant with the suppression of iNOS and COX-2 expression at both the protein and mRNA levels. We also showed that this inhibition is not associated with changes in NF-kB DNA-binding activity.
The TNF-α  -+  +  +  ---IL-17  ----+  +  +  TSA  --+  --+  -BA  ---+  --+   TNF-α  -+  +  +  ---IL-17  ----+  +  +  TSA  --+  --+  -BA  ---+ 29 showed that another HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), dose-dependently attenuated NO release from mouse peritoneal macrophages stimulated by the combination of TNF-a and IFN-g. Similarly, Larsen et al. 42 found that TSA and SAHA prevented the production of NO and the expression of iNOS in the b-cell line INS-1 and in intact rat islets treated with IL-1 þ IFN-g 42 On the other hand, TSA and SAHA have been shown to enhance LPS-induced production of NO in microglial cells 43 , and butyrate was reported to increase the expression of iNOS and the production of NO in response to treatment with LPS þ IFN-g in intestinal epithelial cells 44 . The reasons for these discrepancies are unclear but may be attributable to several factors including cell type and stimulation conditions. We also demonstrated that TSA and BA prevented IL-1-induced PGE 2 release in chondrocytes. Furthermore, TSA and BA suppressed IL-1-induced COX-2 expression at the mRNA and protein levels. These findings are in agreement with previous studies showing that HDAC inhibitors prevented the induction of PGE 2 production and COX-2 expression in several cell types 45, 46 . Pro-inflammatory cytokines TNF-a and IL-17 are also believed to contribute to the pathogenesis of OA and are strong inducers of NO and PGE 2 synthesis in chondrocytes 1e3 . Interestingly, HDAC inhibitors blocked the production of NO and PGE 2 in chondrocytes treated with either TNF-a or IL-17. Thus, the suppression of NO and PGE 2 synthesis by HDAC inhibitors is not specific to IL-1 and is independent of the nature of the stimulus that triggers NO and PGE 2 production.
Several studies have demonstrated that HDAC inhibitors suppress the production of a number of pro-inflammatory cytokines in vitro and in vivo. For example, treatment with SAHA or ITF2357 decreased the release of IL-1, IL-12, TNF-a and IFN-g from LPS-stimulated human peripheral blood mononuclear cells 29, 30 . TSA treatment was also reported to prevent the expression of IL-8 in Caco-2 cells 47 and of IL-12 in lung epithelial cells stimulated with LPS 48 . In vivo, SAHA dose-dependently reduced the circulating levels of the pro-inflammatory cytokines TNF-a, IL-1, and IL-6 in an endotoxemia model 29 . In addition to their anti-inflammatory effects, HDAC inhibitors display 49 showed that HDAC inhibitors blocked the induction of several enzymes responsible for cartilage degradation, including MMP-1, MMP-13, a disintegrin and metalloproteinase domain with thrombospondin motifs (ADAMTS) -4, -5 and -9 and prevented cartilage degradation in an explant assay 49 . Together these data suggest that HDAC inhibitors may prevent cartilage destruction in arthritis. Indeed, HDAC inhibitors prevent cartilage damage in models of adjuvant-induced arthritis 50 and autoantibodymediated arthritis 51 . Protective effects of HDAC inhibitors on cartilage were also observed in collagen-induced arthritis models 52 . The transcription factor NF-kB is important in the induction of iNOS and COX-2 by pro-inflammatory cytokines and stimuli in chondrocytes, and the 5 0 -flanking regions of both iNOS and COX-2 genes contain binding sites for NF-kB 39, 40 . In the present study, we demonstrated that IL-1 enhances the binding activity of NF-kB p65. Interestingly, treatment with TSA or butyrate did not affect the binding activity of NF-kB, suggesting that HDAC inhibitors influence NF-kB-dependent gene expression down-stream of DNA-binding in chondrocytes. These results are in accordance with previous reports showing that HDAC inhibitors did not affect the DNA-binding activity of NF-kB in IL-1-stimulated mesangial cells 41 , and Caco-2 cells 47 , as well as in LPS-stimulated N9 microglia cells 43 . In contrast, other groups have reported that HDAC inhibitors reduced the DNA-binding activity of NF-kB in A549 cells 53 and human colon cell lines 54 treated with pro-inflammatory cytokines. Several reasons may explain this dichotomy including the differences in time exposure to HDAC inhibitors and the model used.
There are a number of potential mechanisms by which HDAC inhibitors could inhibit IL-1-induced iNOS and COX-2 expression. First, HDAC inhibitors may down-regulate gene expression by altering local chromatin structure secondary to increased histone acetylation. Secondly, the suppressive effect of HDAC inhibitors could be mediated by hyperacetylation of transcription factors or signaling molecules that participate in IL-1-induced iNOS and COX-2 expression. Finally, gene products induced by HDAC inhibitors may also interfere with the signaling pathways involved in iNOS and COX-2 expression. Regardless of the exact mechanism by which HDAC inhibitors down-regulate IL-1-induced NO and PGE 2 production, these results are very interesting from a pharmacological point of view since inhibitors of PGE 2 and NO production are a promising class of compounds with therapeutic potential for OA.
In conclusion, we have shown that HDAC inhibitors suppress IL-1-induced NO and PGE 2 production, iNOS and COX-2 expression as well as proteoglycan degradation. The mechanism by which HDAC inhibitors attenuate IL-1-effects is independent of the DNA-binding activity of the transcription factor NF-kB. These data also suggest that HDAC inhibitors represent a promising new class of compounds in the treatment of OA.
